{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:09:58Z","timestamp":1791727798289,"version":"4.3.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Am Acad Orthop Surg","JAAOS"],"published-print":{"date-parts":[[2026,3,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with relapsed or refractory multiple myeloma (MM) often have a high burden of skeletal disease and may be at risk for pathologic fracture. These patients may be eligible for chimeric antigen receptor T-cell (CAR-T) therapy. However, little is known about the effect of CAR-T therapy on a patient's fracture risk. The purpose of this study is to evaluate this effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A consecutive cohort of MM patients undergoing treatment with CAR-T therapy were reviewed retrospectively. Patients were required to have a PET-CT before CAR-T infusion and at least one PET-CT surveillance imaging 90 days following treatment. The minimum follow-up for surviving patients was set at 3 months. The primary outcome measure was fracture risk as characterized by a modified Mirels criteria. The secondary outcome measure was change in lesion avidity, measured as standardized uptake value units, on PET-CT. Survival was investigated by Kaplan-Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We identified 139 patients who underwent CAR-T for MM. Overall, 71 patients (51.4%) had a discrete long bone lesion, and 37 patients (27.8%) were characterized as being \u201cat risk\u201d for fracture before infusion. After CAR-T, three patients (2.5%) were identified as being at risk (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004). The mean PET-CT standardized uptake value between at risk patients and those at low risk was markedly different before infusion (9.18 vs. 6.75,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03). For these same patients, no difference was identified after CAR-T therapy (5.75 vs. 4.67,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.26). Three fractures occurred in the posttransfusion period; 33 patients (23.7%) died of disease after CAR-T therapy at a mean of 6.6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Following CAR-T infusion, a notable reduction was observed in fracture risk, suggesting that CAR-T could be valuable not only in managing MM but also in managing the risk of pathologic fracture that comes with this malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5435\/jaaos-d-25-00392","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:00:20Z","timestamp":1757970020000},"page":"e926-e933","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Influence of Chimeric Antigen Receptor T-Cell Therapy on Fracture Risk of Patients With Multiple Myeloma"],"prefix":"10.5435","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1335-6762","authenticated-orcid":false,"given":"Thien Huong N.","family":"Huynh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan A.","family":"Clampitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe M.","family":"Chose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Nester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odion T.","family":"Binitie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-1529","authenticated-orcid":false,"given":"Alexander L.","family":"Lazarides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"R1-20260413","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"key":"R2-20260413","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in Lenalidomide-Refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"R3-20260413","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"R4-20260413","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: Pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol"},{"key":"R5-20260413","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-9966-27-11","article-title":"Effect of pathologic fractures on survival in multiple myeloma patients: A case control study","volume":"27","author":"Sonmez","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"key":"R6-20260413","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2019.230011","article-title":"Fractures and survival in multiple myeloma: Results from a population-based study","volume":"105","author":"Thorsteinsdottir","year":"2020","journal-title":"Haematologica"},{"key":"R7-20260413","first-page":"e20.00141","article-title":"Mirels scores in patients undergoing prophylactic stabilization for femoral metastatic bone disease in the veterans administration healthcare system","volume":"4","author":"Ramsey","year":"2020","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1200\/JOP.18.00431","article-title":"Early clinical and economic outcomes of prophylactic and acute pathologic fracture treatment","volume":"15","author":"Mosher","year":"2019","journal-title":"J Oncol Pract"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/CORR.0000000000000489","article-title":"What is the adverse event profile after prophylactic treatment of femoral shaft or distal femur metastases?","volume":"476","author":"McLynn","year":"2018","journal-title":"Clin Orthop Relat Res"},{"key":"R10-20260413","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fmed.2019.00069","article-title":"Interest of pet imaging in multiple myeloma","volume":"6","author":"Jamet","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"R11-20260413","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation [published correction appears in blood. 2012 Sep 13;120(11):2349]","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"R12-20260413","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00259-005-0004-3","article-title":"Role of 18F-FDG PET\/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: Preliminary results","volume":"33","author":"Nanni","year":"2006","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"R13-20260413","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jos.2017.01.006","article-title":"Practical use of imaging technique for management of bone and soft tissue tumors","volume":"22","author":"Miwa","year":"2017","journal-title":"J Orthop Sci"},{"key":"R14-20260413","first-page":"7335","article-title":"An analysis of clinical values of MRI, CT and X-ray in differentiating benign and malignant bone metastases","volume":"13","author":"Xiong","year":"2021","journal-title":"Am J Transl Res"},{"key":"R15-20260413","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/07357907.2013.764565","article-title":"Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey","volume":"31","author":"Princewill","year":"2013","journal-title":"Cancer Invest"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1097\/RLU.0000000000002057","article-title":"99mTc MDP SPECT-CT-Based modified mirels classification for evaluation of risk of fracture in skeletal metastasis: A pilot study","volume":"43","author":"Riaz","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R17-20260413","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2015.00040","article-title":"Current role of radiation therapy for multiple myeloma","volume":"5","author":"Talamo","year":"2015","journal-title":"Front Oncol"}],"container-title":["Journal of the American Academy of Orthopaedic Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-25-00392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:50:36Z","timestamp":1787669436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-25-00392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5435\/jaaos-d-25-00392","relation":{},"ISSN":["1067-151X","1940-5480"],"issn-type":[{"value":"1067-151X","type":"print"},{"value":"1940-5480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"2025-03-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}